Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA:603456)
China · Delayed Price · Currency is CNY 14.15
+0.13 (0.93%)
Apr 28, 2026, 3:00 PM CST
SHA:603456 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 5,219 | 5,509 | 5,086 | 5,406 | 5,181 | 3,823 |
Other Revenue | - | - | 74.24 | 117.58 | 264.29 | 240.52 |
| 5,219 | 5,509 | 5,161 | 5,523 | 5,445 | 4,063 | |
Revenue Growth (YoY) | 0.85% | 6.74% | -6.57% | 1.44% | 34.01% | 53.49% |
Cost of Revenue | 3,310 | 3,479 | 3,571 | 3,524 | 3,623 | 2,746 |
Gross Profit | 1,909 | 2,030 | 1,590 | 1,999 | 1,822 | 1,317 |
Selling, General & Admin | 495.23 | 501.57 | 513.31 | 524.15 | 480.09 | 383.42 |
Research & Development | 245.54 | 256.99 | 314.91 | 330.83 | 287.38 | 173.36 |
Other Operating Expenses | 32.68 | 38.2 | 29.47 | 21.97 | 34.67 | 26.52 |
Operating Expenses | 773.46 | 796.76 | 874.34 | 896.32 | 796.43 | 590.87 |
Operating Income | 1,136 | 1,233 | 715.31 | 1,103 | 1,026 | 725.97 |
Interest Expense | - | - | -19.38 | -21.73 | -22.38 | -24.87 |
Interest & Investment Income | 8.62 | 3.56 | 86.06 | 91.82 | 15.27 | 68.74 |
Currency Exchange Gain (Loss) | - | - | 12.52 | 9.02 | 97.03 | -18.36 |
Other Non Operating Income (Expenses) | 13.54 | 25.56 | -1.33 | -4.27 | -2.02 | -2.29 |
EBT Excluding Unusual Items | 1,158 | 1,262 | 793.18 | 1,178 | 1,114 | 749.19 |
Impairment of Goodwill | - | - | -21.51 | 1.32 | -0.87 | -10.86 |
Gain (Loss) on Sale of Investments | 0.98 | - | -8.13 | -19.36 | -35.22 | -1.39 |
Gain (Loss) on Sale of Assets | -5.77 | -5.16 | -13.54 | -4.03 | -8.85 | -16.57 |
Asset Writedown | -324.18 | -337.76 | -39.11 | -0.13 | - | -5.54 |
Other Unusual Items | - | - | 19.72 | 25.26 | 35.03 | 29.92 |
Pretax Income | 828.79 | 919.45 | 730.6 | 1,181 | 1,104 | 744.74 |
Income Tax Expense | 181.87 | 190.91 | 123.53 | 149.27 | 182.85 | 110.59 |
Earnings From Continuing Operations | 646.92 | 728.54 | 607.07 | 1,031 | 920.97 | 634.15 |
Minority Interest in Earnings | 5.04 | 1.53 | -0.97 | 1.88 | 0.2 | -0.25 |
Net Income | 651.95 | 730.07 | 606.1 | 1,033 | 921.17 | 633.9 |
Net Income to Common | 651.95 | 730.07 | 606.1 | 1,033 | 921.17 | 633.9 |
Net Income Growth | 5.23% | 20.46% | -41.34% | 12.17% | 45.32% | 66.56% |
Shares Outstanding (Basic) | 893 | 890 | 891 | 891 | 830 | 823 |
Shares Outstanding (Diluted) | 893 | 890 | 891 | 891 | 830 | 834 |
Shares Change (YoY) | 0.71% | -0.11% | 0.07% | 7.33% | -0.50% | 3.00% |
EPS (Basic) | 0.73 | 0.82 | 0.68 | 1.16 | 1.11 | 0.77 |
EPS (Diluted) | 0.73 | 0.82 | 0.68 | 1.16 | 1.11 | 0.76 |
EPS Growth | 4.49% | 20.59% | -41.38% | 4.50% | 46.05% | 61.70% |
Free Cash Flow | 1,040 | 1,164 | 102.69 | 430.88 | 511.99 | 97.64 |
Free Cash Flow Per Share | 1.17 | 1.31 | 0.12 | 0.48 | 0.62 | 0.12 |
Dividend Per Share | - | - | 0.300 | 0.500 | 0.400 | 0.250 |
Dividend Growth | - | - | -40.00% | 25.00% | 60.00% | 25.00% |
Gross Margin | 36.58% | 36.85% | 30.80% | 36.19% | 33.47% | 32.41% |
Operating Margin | 21.76% | 22.39% | 13.86% | 19.96% | 18.84% | 17.87% |
Profit Margin | 12.49% | 13.25% | 11.74% | 18.71% | 16.92% | 15.60% |
Free Cash Flow Margin | 19.93% | 21.13% | 1.99% | 7.80% | 9.40% | 2.40% |
EBITDA | 1,555 | 1,648 | 1,109 | 1,479 | 1,369 | 1,017 |
EBITDA Margin | 29.80% | 29.91% | 21.50% | 26.77% | 25.13% | 25.04% |
D&A For EBITDA | 419.44 | 414.36 | 394.04 | 376.06 | 342.67 | 291.37 |
EBIT | 1,136 | 1,233 | 715.31 | 1,103 | 1,026 | 725.97 |
EBIT Margin | 21.76% | 22.39% | 13.86% | 19.96% | 18.84% | 17.87% |
Effective Tax Rate | 21.94% | 20.76% | 16.91% | 12.64% | 16.56% | 14.85% |
Revenue as Reported | - | - | 5,161 | 5,523 | 5,445 | 4,063 |
Updated Mar 31, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.